Skip to content

Amyotrophic Lateral Sclerosis: a New Paradigm

Amyotrophic Lateral Sclerosis: a New Paradigm

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03073239
Acronym
ALSParadigm
Enrollment
30
Registered
2017-03-08
Start date
2016-12-31
Completion date
2018-06-30
Last updated
2018-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

Keywords

Amyotrophic Lateral Sclerosis, Bulbar disfunction, Rik factors ALS

Brief summary

Amyotrophic Lateral Sclerosis (ALS) is a degenerative neuromuscular disease, progressing inexorably to respiratory failure, the by involvement of respiratory muscles, the commitment with most impact on the prognosis of ALS. According to current knowledge, the clinical presentation of the disease is characterized by spinal or bulbar involvement, the latter being associated with a worse prognosis. There are multiple factors described in the aetiology of ALS, as the successive damage the motor neuron, which can happen in high-impact athletes, or exposure to heavy metals. Genetic mutations are also described, being associated to a higher prevalence of ALS. Data from retrospective studies with ALS populations reveal a prevalence of 4-8 cases per 100,000 persons. Research carried out in Trás-os-Montes e Alto Douro region (Northeast of Portugal) shows a high prevalence of ALS, with near 10 cases per 100,000 persons, with a recent increase in the bulbar involvement. The reasons for the high prevalence of ALS in this region are unknown.

Detailed description

The objective of this research is to pursue potentially involved genetic mutations in this disease (new or previously described), in addition to carry out a epidemiological questionnaire including data on personal history, environmental and occupational exposure that might be underlying this high prevalence.

Interventions

GENETICALS patients genetic characterization

Genetic findings in ALS patients

OTHERALS patients epidemiological caracterization

Epidemiological characterization in ALS patients

Sponsors

Conde, Bebiana, M.D.
Lead SponsorINDIV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All patients with Amyotrophic Lateral Sclerosis sent to a medical consultation

Exclusion criteria

* Amyotrophic Lateral Sclerosis not confirmed * Ages less than 18 years old

Design outcomes

Primary

MeasureTime frameDescription
Finding environmental risk factor2 yearsApply epidemiogycal form to All ALS patients sentido to respiratory evaluation in 2 years.

Secondary

MeasureTime frameDescription
Regional prevalence1 yearIdentify All cases ALS in regional area ( in north of Portugal)
Finding a genetic marker2 yearsScan all ALS patients to eventually finding new ALS genes

Countries

Portugal

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026